NASDAQ:OPTN - OptiNose Stock Price, Price Target & More

$21.12 +0.64 (+3.13 %)
(As of 04/27/2018 04:47 AM ET)
Previous Close$20.48
Today's Range$20.72 - $21.27
52-Week Range$15.01 - $25.24
Volume48,162 shs
Average Volume73,253 shs
Market Capitalization$766.78 million
P/E Ratio-3.75
Dividend YieldN/A
BetaN/A

About OptiNose (NASDAQ:OPTN)

OptiNose logoOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.

Receive OPTN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPTN
CUSIPN/A
Phone267-364-3500

Debt

Debt-to-Equity Ratio0.47%
Current Ratio16.13%
Quick Ratio15.99%

Price-To-Earnings

Trailing P/E Ratio-3.75
Forward P/E Ratio-7.04
P/E GrowthN/A

Sales & Book Value

Annual Sales$47.50 million
Price / Sales16.84
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book5.16

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees82
Outstanding Shares37,870,000

OptiNose (NASDAQ:OPTN) Frequently Asked Questions

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

How were OptiNose's earnings last quarter?

OptiNose (NASDAQ:OPTN) announced its quarterly earnings results on Tuesday, March, 13th. The company reported ($0.64) EPS for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.18. View OptiNose's Earnings History.

What price target have analysts set for OPTN?

4 analysts have issued twelve-month target prices for OptiNose's stock. Their forecasts range from $27.00 to $33.00. On average, they expect OptiNose's stock price to reach $29.25 in the next year. View Analyst Ratings for OptiNose.

Who are some of OptiNose's key competitors?

Who are OptiNose's key executives?

OptiNose's management team includes the folowing people:
  • Mr. Peter K. Miller, CEO & Director (Age 57)
  • Dr. Ramy A. Mahmoud, Pres and Chief Operating Officer (Age 53)
  • Mr. Thomas E. Gibbs, Chief Commercial Officer (Age 46)
  • Mr. Keith Alan Goldan, Chief Financial Officer (Age 47)
  • Ms. Ricci Whitlow, VP of Technical Operations

When did OptiNose IPO?

(OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

When did the company's lock-up period expire?

OptiNose's lock-up period expired on Wednesday, April 11th. OptiNose had issued 7,500,000 shares in its public offering on October 13th. The total size of the offering was $120,000,000 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

Has OptiNose been receiving favorable news coverage?

Media stories about OPTN stock have been trending positive this week, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OptiNose earned a news sentiment score of 0.26 on Accern's scale. They also gave news stories about the company an impact score of 46.62 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of OptiNose?

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $21.12.

How big of a company is OptiNose?

OptiNose has a market capitalization of $766.78 million and generates $47.50 million in revenue each year. The company earns $-48,900,000.00 in net income (profit) each year or ($5.63) on an earnings per share basis. OptiNose employs 82 workers across the globe.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]


MarketBeat Community Rating for OptiNose (OPTN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  137
MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OptiNose (NASDAQ:OPTN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for OptiNose in the last 12 months. Their average twelve-month price target is $29.25, suggesting that the stock has a possible upside of 38.49%. The high price target for OPTN is $33.00 and the low price target for OPTN is $27.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.25$29.25$29.25N/A
Price Target Upside: 38.49% upside47.21% upside47.21% upsideN/A

OptiNose (NASDAQ:OPTN) Consensus Price Target History

Price Target History for OptiNose (NASDAQ:OPTN)

OptiNose (NASDAQ:OPTN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/15/2018Piper JaffraySet Price TargetBuy$28.00MediumView Rating Details
11/7/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$33.00N/AView Rating Details
11/7/2017Jefferies GroupInitiated CoverageBuy -> Buy$27.00N/AView Rating Details
11/7/2017BMO Capital MarketsInitiated CoverageOutperform$29.00N/AView Rating Details
(Data available from 4/27/2016 forward)

Earnings

OptiNose (NASDAQ:OPTN) Earnings History and Estimates Chart

Earnings by Quarter for OptiNose (NASDAQ:OPTN)

OptiNose (NASDAQ:OPTN) Earnings Estimates

2018 EPS Consensus Estimate: ($2.93)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.74)($0.74)($0.74)
Q2 20181($0.74)($0.74)($0.74)
Q3 20181($0.72)($0.72)($0.72)
Q4 20181($0.73)($0.73)($0.73)

OptiNose (NASDAQ OPTN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018Y 2017($0.46)($0.64)ViewN/AView Earnings Details
11/27/2017Q3 2017($0.47)($4.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

OptiNose (NASDAQ:OPTN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

OptiNose (NASDAQ OPTN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 29.45%
Insider Trading History for OptiNose (NASDAQ:OPTN)
Institutional Ownership by Quarter for OptiNose (NASDAQ:OPTN)

OptiNose (NASDAQ OPTN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2018Peter K MillerCEOBuy5,054$18.58$93,903.32View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

OptiNose (NASDAQ OPTN) News Headlines

Source:
DateHeadline
Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia AreaOptinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia Area
www.nasdaq.com - April 24 at 10:07 AM
Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia AreaOptinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia Area
finance.yahoo.com - April 24 at 10:07 AM
Brokerages Expect OptiNose (OPTN) to Post ($0.74) Earnings Per ShareBrokerages Expect OptiNose (OPTN) to Post ($0.74) Earnings Per Share
www.americanbankingnews.com - April 13 at 3:29 AM
 Brokerages Expect OptiNose (OPTN) Will Post Earnings of -$0.74 Per Share Brokerages Expect OptiNose (OPTN) Will Post Earnings of -$0.74 Per Share
www.americanbankingnews.com - April 11 at 7:17 PM
OptiNose (OPTN) Expected to Post FY2022 Earnings of $2.14 Per ShareOptiNose (OPTN) Expected to Post FY2022 Earnings of $2.14 Per Share
www.americanbankingnews.com - April 9 at 2:32 AM
Investors Should Opt Out Of OptiNose Before IPO Lock-Up ExpiresInvestors Should Opt Out Of OptiNose Before IPO Lock-Up Expires
seekingalpha.com - April 4 at 5:44 PM
OptiNose Incs Lock-Up Period Set To End  on April 11th (NASDAQ:OPTN)OptiNose Inc's Lock-Up Period Set To End on April 11th (NASDAQ:OPTN)
www.americanbankingnews.com - April 4 at 1:20 AM
BMO Capital Markets Begins Coverage on OptiNose (OPTN)BMO Capital Markets Begins Coverage on OptiNose (OPTN)
www.americanbankingnews.com - April 1 at 4:48 PM
OptiNose (OPTN) Coverage Initiated by Analysts at Jefferies GroupOptiNose (OPTN) Coverage Initiated by Analysts at Jefferies Group
www.americanbankingnews.com - April 1 at 4:48 PM
Piper Jaffray Begins Coverage on OptiNose (OPTN)Piper Jaffray Begins Coverage on OptiNose (OPTN)
www.americanbankingnews.com - April 1 at 4:16 PM
OptiNose (OPTN) Now Covered by Analysts at Royal Bank of CanadaOptiNose (OPTN) Now Covered by Analysts at Royal Bank of Canada
www.americanbankingnews.com - April 1 at 4:16 PM
 OptiNose Inc (OPTN) Receives Consensus Recommendation of "Strong Buy" from Analysts OptiNose Inc (OPTN) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 29 at 9:32 PM
Piper Jaffray Analysts Give OptiNose (OPTN) a $28.00 Price TargetPiper Jaffray Analysts Give OptiNose (OPTN) a $28.00 Price Target
www.americanbankingnews.com - March 28 at 3:48 PM
Zacks: OptiNose Inc (OPTN) Receives Average Recommendation of "Strong Buy" from BrokeragesZacks: OptiNose Inc (OPTN) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 24 at 11:22 PM
Award time: Life Sciences Pennsylvania hands out annual industry awardsAward time: Life Sciences Pennsylvania hands out annual industry awards
finance.yahoo.com - March 19 at 4:03 PM
Peter K. Miller Buys 5,054 Shares of OptiNose Inc (OPTN) StockPeter K. Miller Buys 5,054 Shares of OptiNose Inc (OPTN) Stock
www.americanbankingnews.com - March 19 at 10:19 AM
 OptiNose Inc (OPTN) Receives Consensus Rating of "Strong Buy" from Analysts OptiNose Inc (OPTN) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - March 18 at 10:20 AM
OptiNose (OPTN) Stock Rating Lowered by Zacks Investment ResearchOptiNose (OPTN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 17 at 2:09 PM
Optinose Named Emerging Company of the Year by Life Sciences PennsylvaniaOptinose Named Emerging Company of the Year by Life Sciences Pennsylvania
finance.yahoo.com - March 16 at 11:14 AM
OptiNose Inc (OPTN) Expected to Post Q1 2018 Earnings of ($0.74) Per ShareOptiNose Inc (OPTN) Expected to Post Q1 2018 Earnings of ($0.74) Per Share
www.americanbankingnews.com - March 16 at 8:12 AM
OptiNose (OPTN) Issues  Earnings Results, Misses Expectations By $0.18 EPSOptiNose (OPTN) Issues Earnings Results, Misses Expectations By $0.18 EPS
www.americanbankingnews.com - March 14 at 9:50 AM
 OptiNose Inc (OPTN) Given $29.25 Average Price Target by Analysts OptiNose Inc (OPTN) Given $29.25 Average Price Target by Analysts
www.americanbankingnews.com - March 14 at 3:26 AM
Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational HighlightsOptinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - March 13 at 11:45 AM
OptiNose reports 4Q lossOptiNose reports 4Q loss
finance.yahoo.com - March 13 at 11:45 AM
-$0.46 Earnings Per Share Expected for OptiNose Inc (OPTN) This Quarter-$0.46 Earnings Per Share Expected for OptiNose Inc (OPTN) This Quarter
www.americanbankingnews.com - March 8 at 4:14 PM
Zacks: OptiNose Inc (OPTN) Given Consensus Rating of "Strong Buy" by AnalystsZacks: OptiNose Inc (OPTN) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - March 8 at 3:28 AM
Optinose to Report Fourth Quarter and Full Year 2017 Financial Results and Corporate Updates on March 13, 2018Optinose to Report Fourth Quarter and Full Year 2017 Financial Results and Corporate Updates on March 13, 2018
finance.yahoo.com - March 7 at 11:04 AM
Next Century Growth Investors LLC Takes $2.01 Million Position in OptiNose Inc (OPTN)Next Century Growth Investors LLC Takes $2.01 Million Position in OptiNose Inc (OPTN)
www.americanbankingnews.com - March 4 at 2:31 PM
Optinose to Highlight Data at the 2018 AAAAI/WAO Joint CongressOptinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress
finance.yahoo.com - February 27 at 10:54 AM
92,317 Shares in OptiNose Inc (OPTN) Acquired by American Century Companies Inc.92,317 Shares in OptiNose Inc (OPTN) Acquired by American Century Companies Inc.
www.americanbankingnews.com - February 27 at 4:06 AM
Optinose names Sandra L. Helton as Director and Chairperson of the Company’s Audit CommitteeOptinose names Sandra L. Helton as Director and Chairperson of the Company’s Audit Committee
finance.yahoo.com - February 23 at 10:37 AM
Brokerages Expect OptiNose Inc (OPTN) to Post ($0.46) Earnings Per ShareBrokerages Expect OptiNose Inc (OPTN) to Post ($0.46) Earnings Per Share
www.americanbankingnews.com - February 21 at 12:12 PM
Peter Miller Named Frank Baldino Bioscience CEO of the Year by Life Sciences PennsylvaniaPeter Miller Named Frank Baldino Bioscience CEO of the Year by Life Sciences Pennsylvania
finance.yahoo.com - February 21 at 11:10 AM
OptiNose Inc (OPTN) Expected to Post Earnings of -$0.46 Per ShareOptiNose Inc (OPTN) Expected to Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - February 19 at 9:10 PM
Critical Comparison: OptiNose (OPTN) versus Albany Molecular Research (AMRI)Critical Comparison: OptiNose (OPTN) versus Albany Molecular Research (AMRI)
www.americanbankingnews.com - February 18 at 9:12 PM
Optinose to Present at the 2018 RBC Capital Markets Healthcare ConferenceOptinose to Present at the 2018 RBC Capital Markets Healthcare Conference
finance.yahoo.com - February 15 at 3:55 PM
Optinose to Present at Leerink Partners 7th Annual Global Healthcare ConferenceOptinose to Present at Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 3:25 PM
 Brokerages Set $29.25 Price Target for OptiNose Inc (OPTN) Brokerages Set $29.25 Price Target for OptiNose Inc (OPTN)
www.americanbankingnews.com - February 6 at 9:30 PM
 OptiNose Inc (OPTN) Given $29.25 Consensus Price Target by Analysts OptiNose Inc (OPTN) Given $29.25 Consensus Price Target by Analysts
www.americanbankingnews.com - January 31 at 1:34 AM
Zacks: Brokerages Set $29.25 Price Target for OptiNose Inc (OPTN)Zacks: Brokerages Set $29.25 Price Target for OptiNose Inc (OPTN)
www.americanbankingnews.com - January 25 at 11:40 AM
 OptiNose Inc (OPTN) Given $29.67 Average Target Price by Analysts OptiNose Inc (OPTN) Given $29.67 Average Target Price by Analysts
www.americanbankingnews.com - January 10 at 10:38 AM
[$$] Publicly Traded OptiNose Seals $100 Million Debt Deal With Athyrium[$$] Publicly Traded OptiNose Seals $100 Million Debt Deal With Athyrium
finance.yahoo.com - January 2 at 7:45 PM
Zacks: OptiNose Inc (OPTN) Given $29.67 Consensus Price Target by BrokeragesZacks: OptiNose Inc (OPTN) Given $29.67 Consensus Price Target by Brokerages
www.americanbankingnews.com - December 24 at 9:53 PM
Zacks: OptiNose Inc (OPTN) Given Average Recommendation of "Strong Buy" by AnalystsZacks: OptiNose Inc (OPTN) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - December 21 at 5:40 PM
Optinose IncOptinose Inc
www.bloomberg.com - December 14 at 6:31 PM
Head to Head Contrast: OptiNose (OPTN) & Its PeersHead to Head Contrast: OptiNose (OPTN) & Its Peers
www.americanbankingnews.com - December 11 at 11:26 AM
Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of DirectorsMinerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors
finance.yahoo.com - December 11 at 9:23 AM
Head to Head Survey: OptiNose (OPTN) versus Its CompetitorsHead to Head Survey: OptiNose (OPTN) versus Its Competitors
www.americanbankingnews.com - December 8 at 9:28 AM
Optinose to Present at BMO Capital Markets Prescription for Success Healthcare ConferenceOptinose to Present at BMO Capital Markets Prescription for Success Healthcare Conference
finance.yahoo.com - December 7 at 6:37 PM
 OptiNose Inc (OPTN) Given Consensus Recommendation of "Strong Buy" by Brokerages OptiNose Inc (OPTN) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 5 at 1:38 AM

SEC Filings

OptiNose (NASDAQ:OPTN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OptiNose (NASDAQ:OPTN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OptiNose (NASDAQ OPTN) Stock Chart for Friday, April, 27, 2018

Loading chart…

This page was last updated on 4/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.